Advances in precision medicine approaches, including genomic profiling, can provide valuable insights into the molecular characteristics of gliomas and help identify patient subgroups that are more likely to benefit from PI3K-targeted therapies. The gene discussed is PIK3CA; the disease is central nervous system cancer.